References
- Durie B GM, Harousseau J-L, Miguel J S, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473
- Sarasquete M E, Garcia-Sanz R, Gonzalez D, Martnez J, Mateo G, Martinez, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005; 90: 1365–1372
- Wei A, Westerman D, Feleppa F, Trivett M, Juneja S. Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma. Haematologica 2005; 90: 1147–1149
- Morice W G, Hanson C A, Kumar S, Fredrick L A, Lesnick C E, Greipp P R. Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. Leukaemia 2007; 21: 2043–2083
- de Tute R M, Jack A S, Child J A, Morgan G J, Owen R G, Rawstron A C. A single tube six-colour assay for the detection of minimal residual disease in myeloma. Leukaemia 2007; 21: 2046–2049
- Owen R G, Rawstron A C. Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice. Br J Haematol 2005; 128: 732–733
- Liu H, Yuan C, Heinerich J, Braylan R, Chang M, Wingard J, et al. Flow cytometric disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: A retrospective study. Leuk Lymph 2008; 49: 306–314
- Bakkus M HC, Bouko Y, Samson D, Apperly J F, Thielemans K, Van Camp B, et al. Post-transplantation tumour load in bone marrow assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br J Haematol 2004; 126: 665–674